Overview
Dr. Datto is an AP/CP/MGP board certified pathologist who specializes in molecular pathology. He is the Associate Vice President for Duke University Health System Clinical Laboratories, the Vice Chair for Clinical Pathology and Medical Director for Duke University Health System Clinical Laboratories.
In these roles, he is responsible for maintaining the standards of the College of American Pathologists and CLIA/CMS within all Clinical Laboratories at Duke. Specifically, Dr. Datto oversees clinical testing and reporting, develops quality management systems and proficiency testing programs, provides consultation with ordering physicians, ensures educational programs, develops strategic plans that are in line with the needs of our patient population, physicians and health system leadership, coordinates research and development, ensures adequate and appropriately trained personnel, and provides profession interpretation for molecular diagnostic testing including the wide range of PCR, quantitative PCR, sequencing and FISH based tests for inherited genetic diseases, hematologic malignancies, solid tumors and infectious diseases.
Dr. Datto also serves as the chair of the Accreditation Committee (AC) for the College of American Pathologists (CAP). The CAP is the largest accreditor of hospital based laboratories in the US and serves as a ‘deemed entity’ by the Center for Medicare Services. In his role of chair of the AC, Dr. Datto oversees the committee that makes clinical accreditation decisions for approximately 7,000 clinical domestic and international laboratories.
Finally, Dr. Datto has an active academic program developing data system to aggregate, normalize and utilize high complexity and high volume laboratory data. Dr. Datto and his team have developed the Molecular Registry of Tumors (Mr.T); a software solution that supports clinical trials matching, engagement with the AACR GENIE Project and the Molecular Tumor Board for Duke University Health System. The ultimate goal of this work is to ensure that the vast amount of laboratory data generated on our Duke patients can be put to use, driving better patient care, research and education.
Current Appointments & Affiliations
Recent Publications
Retrieval-augmented generation for interpreting clinical laboratory regulations using large language models
Journal Article Journal of Pathology Informatics · November 1, 2025 Large language models (LLMs) have demonstrated strong performance on general knowledge tasks, but they have important limitations as standalone tools for question answering in specialized domains where accuracy and consistency are critical. Retrieval-augme ... Full text CiteAnalytical validation (accuracy, reproducibility, limit of detection) and gene expression analysis of FoundationOneRNA assay for fusion detection in 189 clinical tumor specimens.
Journal Article PLoS One · 2025 Targeted DNA-based comprehensive genomic profiling (CGP) to detect clinically significant alterations is increasingly becoming standard for patients with advanced or recurrent cancer. RNA-based sequencing, however, may improve performance of fusion detecti ... Full text Link to item CiteExpansion of an Academic Molecular Tumor Board to Enhance Access to Biomarker-Driven Trials and Therapies in the Rural Southeastern United States.
Journal Article Curr Oncol · November 16, 2024 Targeting tumor-specific molecular alterations has shown significant clinical benefit. Molecular tumor boards (MTBs) connect cancer patients with personalized treatments and clinical trials. However, rural cancer centers often have limited access to MTB ex ... Full text Link to item CiteRecent Grants
Cooperative Human Tissue Network Support through Duke's BioRepository & Precision Pathology Center
ResearchCo Investigator · Awarded by National Cancer Institute · 2019 - 2029Adapting K-MDS to detect KRAS-mutant ctDNA
ResearchCo Investigator · Awarded by National Institutes of Health · 2022 - 2025Diffraction tomography for accurate digital pathology on a portable microscope
ResearchCollaborator · Awarded by AiriLabs LLC · 2022 - 2023View All Grants